Home › Bile Duct Cancer (Cholangiocarcinoma)
Bile Duct Cancer (Cholangiocarcinoma) clinical trials recruiting in the U.S.
56 studies for Bile Duct Cancer (Cholangiocarcinoma) are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX13 studies
- New York City, NY11 studies
- Boston, MA8 studies
- Rochester, MN7 studies
- Arlington, VA7 studies
- Los Angeles, CA7 studies
- Chicago, IL7 studies
- Columbus, OH6 studies
- Cleveland, OH6 studies
- Edison, NJ5 studies
- Queens, NY5 studies
- Grand Rapids, MI5 studies
- Nashville, TN5 studies
- Philadelphia, PA5 studies
- San Antonio, TX5 studies
- Tampa, FL5 studies
- Mountain View, CA5 studies
- Miami, FL5 studies
- Baltimore, MD5 studies
- Washington, DC5 studies
- Baldwin Park, CA5 studies
- Dallas, TX5 studies
- Orange, CA4 studies
- St. Louis, MO4 studies
- Durham, NC4 studies
- Seattle, WA4 studies
- Detroit, MI4 studies
- New Haven, CT4 studies
- Atlanta, GA3 studies
- West Valley City, UT3 studies
- Jacksonville, FL3 studies
- Salt Lake City, UT3 studies
- San Francisco, CA3 studies
- Birmingham, AL3 studies
- Buffalo, NY3 studies
- Louisville, KY3 studies
- Santa Monica, CA3 studies
By state
- Alabama3 studies
- Arizona3 studies
- California20 studies
- Colorado3 studies
- Connecticut6 studies
- Florida13 studies
- Georgia3 studies
- Illinois8 studies
- Kentucky4 studies
- Maryland9 studies
- Massachusetts10 studies
- Michigan8 studies
- Minnesota10 studies
- Missouri5 studies
- New Jersey8 studies
- New York15 studies
- North Carolina6 studies
- Ohio10 studies
- Pennsylvania5 studies
- Tennessee5 studies
- Texas15 studies
- Utah6 studies
- Virginia10 studies
- Washington4 studies
- Wisconsin4 studies
Recently updated studies
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT06728410Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT03942328Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
RecruitingObservational study
Ages 2 and older · All sexes · Updated Oct 5, 2026 · NCT01915225A Study of PHST001 in Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT06840886A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06270706Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT04645160PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
RecruitingPhase 2
Ages 18 to 120 · All sexes · Updated Oct 1, 2026 · NCT05286814A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07265674[18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07673341Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06302621Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
RecruitingPhase 2
Ages 19 and older · All sexes · Updated Sep 22, 2026 · NCT07146646A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07213791A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07488676Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT06282575Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT07780838Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT05732831Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 8, 2026 · NCT07282912Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
Recruiting
Ages 18 and older · All sexes · Updated Aug 31, 2026 · NCT05497531AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT07619313Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT04891289HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
Recruiting
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT06899152Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT07486713TCR1188-ABC Cells in KRAS-mutated Cancers
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT07594067Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT05285358D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT06622057From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.